{
  "query": "adverse recurrence cancer grades",
  "studies": {
    "protocolSection": [
      {
        "identificationModule": {
          "nctId": "NCT05653622",
          "briefTitle": "Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma Multiforme, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 75,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02468557",
          "briefTitle": "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-04-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Previously Untreated Pancreatic Ductal Adenocarcinoma", "Relapsed/Refractory Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06674382",
          "briefTitle": "Haplo-HSCT for Myelofibrosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Myelofibrosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06155383",
          "briefTitle": "Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07247396",
          "briefTitle": "CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peritoneal Metastases From Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05022342",
          "briefTitle": "Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01803269",
          "briefTitle": "Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-03-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Extensive Stage Small Cell Lung Cancer", "Recurrent Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01644799",
          "briefTitle": "Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2017-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Follicular Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128501",
          "briefTitle": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia", "Therapy-Related Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03320330",
          "briefTitle": "Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Malignant Solid Neoplasm", "Recurrent Osteosarcoma", "Refractory Malignant Solid Neoplasm", "Refractory Osteosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "30 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02028507",
          "briefTitle": "Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-01-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 693,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00283244",
          "briefTitle": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2014-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 147,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02564198",
          "briefTitle": "A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pediatric Solid Tumor", "Refractory Tumor", "Recurrent Tumor", "CNS Malignancies"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04890236",
          "briefTitle": "Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-09-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04608487",
          "briefTitle": "Axi-cel in CNS Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2038-06-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma", "Lymphoma Cns"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06876844",
          "briefTitle": "Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Head and Neck Cancer Squamous Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03741244",
          "briefTitle": "TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 211,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03971409",
          "briefTitle": "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Triple-Negative Breast Carcinoma", "Unresectable Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00390299",
          "briefTitle": "Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Mixed Glioma", "Recurrent Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03196232",
          "briefTitle": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-05-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Unresectable Esophageal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02630004",
          "briefTitle": "Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-11"
          },
          "completionDateStruct": {
            "date": "2017-12-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Oral Mucositis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 84,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01964430",
          "briefTitle": "Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the \"Apact\" Study)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Neoplasms", "Digestive System Neoplasms", "Neoplasms by Site", "Neoplasms", "Endocrine Gland Neoplasms", "Pancreatic Diseases", "Digestive System Diseases", "Endocrine System Diseases", "Gemcitabine", "Antimetabolites, Antineoplastic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 866,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04409314",
          "briefTitle": "Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-04-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Aggressive Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Malignant Neoplasm", "Recurrent Plasma Cell Myeloma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Refractory Aggressive Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Malignant Neoplasm", "Refractory Plasma Cell Myeloma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00990652",
          "briefTitle": "Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04575961",
          "briefTitle": "Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Low Grade Serous Carcinoma", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06252870",
          "briefTitle": "Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Graft Versus Host Disease", "Hematologic Malignancy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01939483",
          "briefTitle": "A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12"
          },
          "completionDateStruct": {
            "date": "2018-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Central Nervous System Metastases", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03325166",
          "briefTitle": "Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Carcinoma Metastatic in the Brain", "Stage IV Lung Non-Small Cell Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02846766",
          "briefTitle": "Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04478695",
          "briefTitle": "Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06970275",
          "briefTitle": "To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-01-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancers", "Breast Cancer", "Head and Neck Cancer", "Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 850,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00429572",
          "briefTitle": "Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1998-01"
          },
          "completionDateStruct": {
            "date": "2008-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00823719",
          "briefTitle": "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2011-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04150965",
          "briefTitle": "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Relapsed Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06816771",
          "briefTitle": "Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rhabdomyosarcoma, Recurrent, Refractory"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00632281",
          "briefTitle": "Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-01"
          },
          "completionDateStruct": {
            "date": "2008-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03903419",
          "briefTitle": "Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-08-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastomas"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02467907",
          "briefTitle": "Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01264432",
          "briefTitle": "Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-11-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Solid Neoplasm", "Peritoneal Carcinomatosis", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05167851",
          "briefTitle": "The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03399539",
          "briefTitle": "Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-02-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Plasma Cell Myeloma", "T(11;14)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02446600",
          "briefTitle": "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Tumor", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Tumor", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 579,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07022834",
          "briefTitle": "Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Langerhans Cell Histiocytosis (LCH)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "0 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02359565",
          "briefTitle": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-21",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 110,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "30 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00684645",
          "briefTitle": "Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-06"
          },
          "completionDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 186,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05464667",
          "briefTitle": "Preoperative Irradiation for Stage I Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-07-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "50 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06210971",
          "briefTitle": "Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00331344",
          "briefTitle": "Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-04"
          },
          "completionDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04016675",
          "briefTitle": "Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2035-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Malignant Tumor of Lacrimal Drainage Structure"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 94,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05965531",
          "briefTitle": "Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06652412",
          "briefTitle": "CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Cancer", "Rectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 124,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02502266",
          "briefTitle": "Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 582,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05642572",
          "briefTitle": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00102531",
          "briefTitle": "Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-01-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2008-03-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Osteosarcoma Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "13 Years",
          "maximumAge": "50 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06832865",
          "briefTitle": "ELISA in Relapsed/Refractory MM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-08-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed Refractory Multiple Myeloma (RRMM)", "Relapsed Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03595592",
          "briefTitle": "Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Invasive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 650,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06692556",
          "briefTitle": "Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cutaneous Squamous Cell Carcinoma (CSCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 266,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04775602",
          "briefTitle": "Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["18F-PSMA", "Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 550,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01399372",
          "briefTitle": "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09"
          },
          "completionDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Lymphoma", "Neurotoxicity", "Radiation Toxicity"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 91,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02713373",
          "briefTitle": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Colorectal Carcinoma", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05914831",
          "briefTitle": "Ultra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Female"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "50 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04921995",
          "briefTitle": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Nasopharyngeal Carcinoma", "Unresectable Nasopharyngeal Carcinoma", "Chemotherapy Effect", "Immunotherapy", "Stereotactic Body Radiation Therapy (SBRT)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "15 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04739202",
          "briefTitle": "Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Adenocarcinoma", "Advanced Gastric Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02427841",
          "briefTitle": "Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01653912",
          "briefTitle": "Dose-finding Study in Platinum-Resistant Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-11"
          },
          "completionDateStruct": {
            "date": "2015-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Platinum-resistant Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05983094",
          "briefTitle": "Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Neoadjuvant Therapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 181,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02450331",
          "briefTitle": "A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Transitional Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 809,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06462001",
          "briefTitle": "BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Transitional Cell Carcinoma", "Transurethral Resection"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05495724",
          "briefTitle": "Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 176,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07274696",
          "briefTitle": "Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Patients Undergoing Open Thyroid Surgery"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 528,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06737146",
          "briefTitle": "Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "High-grade Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05375903",
          "briefTitle": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-muscle Invasive Bladder Cancer", "NMIBC", "Carcinoma in Situ of Bladder", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05116683",
          "briefTitle": "ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Leiomyosarcoma", "Liposarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04037254",
          "briefTitle": "Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Adenocarcinoma", "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04684108",
          "briefTitle": "SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-11-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed or Refractory Multiple Myeloma", "Hematological Malignancy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06571708",
          "briefTitle": "Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Bladder Cancer", "Muscle-Invasive Bladder Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04676997",
          "briefTitle": "Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03941262",
          "briefTitle": "Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Refractory Cancer", "Metastatic Cancer", "Recurrent Cancer", "Unresectable Carcinoma", "Solid Tumor, Adult", "Advanced Cancer", "Advanced Solid Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02207062",
          "briefTitle": "Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-10"
          },
          "completionDateStruct": {
            "date": "2023-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Transformed B-Cell Non-Hodgkin Lymphoma", "Refractory Transformed B-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01501370",
          "briefTitle": "Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-01"
          },
          "completionDateStruct": {
            "date": "2012-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00107718",
          "briefTitle": "Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-11-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2006-05-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05617313",
          "briefTitle": "Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non Small Cell Lung Cancer", "Metastatic NSCLC", "Recurrent Non Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02569320",
          "briefTitle": "HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Plasma Cell Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05904080",
          "briefTitle": "Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05418088",
          "briefTitle": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Lymphoblastic Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent B-Cell Prolymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Indolent Non-Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory B-Cell Prolymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory High Grade B-Cell Lymphoma", "Refractory Indolent Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia", "Refactory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02204761",
          "briefTitle": "Proton Beam Re-Irradiation in Thoracic Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-09-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-09-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Malignant Neoplasm in the Lung", "Recurrent Disease", "Thoracic Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04565496",
          "briefTitle": "Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 59,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06569225",
          "briefTitle": "Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cholangiocarcinoma Resectable"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00889408",
          "briefTitle": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-12-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-07-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia", "Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01312389",
          "briefTitle": "A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2012-08-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03289910",
          "briefTitle": "Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Atypical Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelofibrosis", "Polycythemia Vera", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05136196",
          "briefTitle": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Melanoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Melanoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Unresectable Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04795661",
          "briefTitle": "Immunotherapy in MSI/dMMR Tumors in Perioperative Setting."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Localized Resectable Tumor", "MSI/dMMR"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 240,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04534283",
          "briefTitle": "A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Cancer Metastatic", "BRAF V600E", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "ERK Mutation", "RAF1 Gene Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00889187",
          "briefTitle": "Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-12-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01168232",
          "briefTitle": "Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-11-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Uterine Corpus Sarcoma", "Uterine Carcinosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01156584",
          "briefTitle": "A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-07"
          },
          "completionDateStruct": {
            "date": "2016-08-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00234052",
          "briefTitle": "Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-11-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06545955",
          "briefTitle": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03229278",
          "briefTitle": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.1": [
      {
        "identificationModule": {
          "nctId": "NCT05281471",
          "briefTitle": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "High-grade Serous Ovarian Cancer", "Endometrioid Ovarian Cancer", "Ovarian Clear Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 186,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03507244",
          "briefTitle": "Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leptomeningeal Metastasis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06466798",
          "briefTitle": "Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Ependymoma", "Recurrent Medulloblastoma", "CNS Malignancies"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02748811",
          "briefTitle": "Effect of Geriatric Intervention in Frail Elderly Patients Receiving Chemotherapy for Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05"
          },
          "completionDateStruct": {
            "date": "2019-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06050512",
          "briefTitle": "Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed and Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05000892",
          "briefTitle": "Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Salivary Gland Malignant Neoplasms", "Salivary Gland Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00423293",
          "briefTitle": "Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-12"
          },
          "completionDateStruct": {
            "date": "2016-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Anal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05364645",
          "briefTitle": "Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-25",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03899077",
          "briefTitle": "Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer of Prostate"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 202,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06747728",
          "briefTitle": "Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Brain Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02494063",
          "briefTitle": "Sentinel Lymph Node Biopsy in Patients With Early Stages Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-06"
          },
          "completionDateStruct": {
            "date": "2024-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02838628",
          "briefTitle": "Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-12-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Actinic Keratosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 168,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02101775",
          "briefTitle": "Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-02-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Brenner Tumor", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 124,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07166419",
          "briefTitle": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Indolent Non-Hodgkin Lymphoma", "Recurrent Lymphoblastic Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Refractory Indolent Non-Hodgkin Lymphoma", "Refractory Lymphoblastic Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04595565",
          "briefTitle": "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HER2-negative Breast Cancer", "Triple Negative Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1332,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05498155",
          "briefTitle": "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06159478",
          "briefTitle": "Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Low-grade Glioma", "Pancreatic Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01336894",
          "briefTitle": "Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-05"
          },
          "completionDateStruct": {
            "date": "2017-03-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05078866",
          "briefTitle": "Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colorectal Carcinoma", "Lynch Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06657027",
          "briefTitle": "Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "15 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00073983",
          "briefTitle": "Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10"
          },
          "completionDateStruct": {
            "date": "2010-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "4 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03558945",
          "briefTitle": "Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03245151",
          "briefTitle": "Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-09-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent and Refractory Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05456269",
          "briefTitle": "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Higher Risk Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04323202",
          "briefTitle": "Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-08-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Basal Cell Carcinoma of the Head and Neck"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00331773",
          "briefTitle": "Radiation Therapy in Treating Patients With Stage II Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1116,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00504257",
          "briefTitle": "Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-03"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Cancer", "Ovarian Cancer", "Malignant Tumor of Peritoneum"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03138031",
          "briefTitle": "Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-05-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma Non-resectable"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "15 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05936229",
          "briefTitle": "Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-10-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent B Acute Lymphoblastic Leukemia", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06572631",
          "briefTitle": "Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00424242",
          "briefTitle": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-01"
          },
          "completionDateStruct": {
            "date": "2011-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Metastatic Cancer", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Secondary Myelofibrosis", "Unspecified Adult Solid Tumor, Protocol Specific"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04519879",
          "briefTitle": "White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-05-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Adenocarcinoma", "PSA Failure", "PSA Progression", "Recurrent Prostate Carcinoma", "Stage I Prostate Cancer AJCC v8", "Stage IIA Prostate Cancer AJCC v8", "Stage IIB Prostate Cancer AJCC v8", "Stage IIC Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 133,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00396279",
          "briefTitle": "Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-07-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-02-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["GCT", "Giant Cell Tumor of Bone"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05057702",
          "briefTitle": "Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Medulloblastoma", "Medulloblastoma, Childhood", "Medulloblastoma Recurrent", "Ependymoma", "Ependymoma Malignant", "Ependymoma of Brain"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "39 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04417062",
          "briefTitle": "Olaparib With Ceralasertib in Recurrent Osteosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Osteosarcoma", "Osteosarcoma Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00098527",
          "briefTitle": "FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-10"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Stomach", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03042169",
          "briefTitle": "Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01287520",
          "briefTitle": "A Study of LY2090314 in Patients With Advanced or Metastatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-11"
          },
          "completionDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "25 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03872388",
          "briefTitle": "Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor Negative", "HER2/Neu Negative", "Inflammatory Breast Carcinoma", "Progesterone Receptor Negative", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06897527",
          "briefTitle": "A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-01-13",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms, Endometrial"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01101594",
          "briefTitle": "A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-07"
          },
          "completionDateStruct": {
            "date": "2013-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05000216",
          "briefTitle": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-03-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Rheumatoid Arthritis (RA)", "Systemic Lupus Erythematosus (SLE)", "Pemphigus Vulgaris", "Multiple Sclerosis (MS)", "Systemic Sclerosis (SSc)", "Pediatric SLE", "Juvenile Idiopathic Arthritis (JIA)", "Juvenile Dermatomyositis (JDM)", "Pediatric-Onset Multiple Sclerosis (POMS)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 258,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05979909",
          "briefTitle": "Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Urothelial Carcinoma Ureter", "Urothelial Cancer of Renal Pelvis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01294306",
          "briefTitle": "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-02"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adenosquamous Lung Carcinoma", "Bronchioloalveolar Carcinoma", "Large Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Squamous Cell Lung Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06259058",
          "briefTitle": "Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 96,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04462328",
          "briefTitle": "Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Primary Central Nervous System Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02370238",
          "briefTitle": "A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 194,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00321958",
          "briefTitle": "Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-04"
          },
          "completionDateStruct": {
            "date": "2007-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Barrett Esophagus", "Esophageal Neoplasms", "Deglutition Disorders", "GERD", "Neoplasm"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03660826",
          "briefTitle": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Endometrial Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 288,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07237399",
          "briefTitle": "Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2031-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Oligometastatic Prostate Cancer (OMPC)", "Prostate Cancer (Adenocarcinoma)", "Ablation Techniques"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01943864",
          "briefTitle": "A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-09-19"
          },
          "completionDateStruct": {
            "date": "2016-02-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01611558",
          "briefTitle": "Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-08-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01870726",
          "briefTitle": "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-12-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01663558",
          "briefTitle": "Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05"
          },
          "completionDateStruct": {
            "date": "2016-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anal Dysplasia", "Human Papilloma Virus", "HIV"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05314998",
          "briefTitle": "Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2031-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Ductal Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 394,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "79 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00559949",
          "briefTitle": "Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-12"
          },
          "completionDateStruct": {
            "date": "2016-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Thyroid Gland Carcinoma", "Stage I Thyroid Gland Papillary Carcinoma", "Stage II Thyroid Gland Papillary Carcinoma", "Stage III Thyroid Gland Papillary Carcinoma", "Stage IV Thyroid Gland Papillary Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06623110",
          "briefTitle": "Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "High-Risk Oral Precancerous Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01041482",
          "briefTitle": "A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-11"
          },
          "completionDateStruct": {
            "date": "2013-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00416923",
          "briefTitle": "Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-08"
          },
          "completionDateStruct": {
            "date": "2007-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Brain and Central Nervous System Tumors", "Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05627323",
          "briefTitle": "CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2041-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma Multiforme of Brain"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03727880",
          "briefTitle": "Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Resectable Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05787496",
          "briefTitle": "A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed or Refractory Acute Myeloid Leukemia", "Relapsed or Refractory Chronic Myelomonocytic Leukemia", "Relapsed or Refractory Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01262560",
          "briefTitle": "Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-02"
          },
          "completionDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Dysphagia", "Lung Cancer", "Pain", "Esophagitis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 163,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03568188",
          "briefTitle": "Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 170,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "50 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05154396",
          "briefTitle": "Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "HER2-positive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04127435",
          "briefTitle": "High Dose Rate Interstitial Brachytherapy With Three Dimensional Printing Template for Recurrent Gynecologic Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06859008",
          "briefTitle": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Grade 1 Follicular Lymphoma", "Refractory Grade 2 Follicular Lymphoma", "Refractory Grade 3a Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Splenic Marginal Zone Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05579340",
          "briefTitle": "Postoperative Exercise Training and Colorectal Cancer Liver Metastasis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-04",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer Metastatic to Liver", "Cancer Colorectal"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00301418",
          "briefTitle": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2014-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma Multiforme", "Anaplastic Astrocytoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05757310",
          "briefTitle": "A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Severe Aplastic Anemia", "Refractory Severe Aplastic Anemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03033524",
          "briefTitle": "Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-02-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-06-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02633059",
          "briefTitle": "Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Loss of Chromosome 17p", "Recurrent Plasma Cell Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00910091",
          "briefTitle": "The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-08"
          },
          "completionDateStruct": {
            "date": "2013-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 73,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00045708",
          "briefTitle": "A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-10"
          },
          "completionDateStruct": {
            "date": "2010-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Anaplastic Astrocytoma", "Adult Giant Cell Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07206225",
          "briefTitle": "A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-01-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-muscle Invasive Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 294,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05476796",
          "briefTitle": "Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Esophagus Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 118,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02736617",
          "briefTitle": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00416624",
          "briefTitle": "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-05"
          },
          "completionDateStruct": {
            "date": "2009-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 239,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05432635",
          "briefTitle": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Mantle Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02669017",
          "briefTitle": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03"
          },
          "completionDateStruct": {
            "date": "2019-02-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Hodgkin Lymphoma", "Burkitt's Lymphoma", "Chronic Lymphocytic Leukemia", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Lymphoma, Marginal Zone", "Waldenstrom Macroglobulinemia", "Primary Mediastinal B-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 183,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05076513",
          "briefTitle": "Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Glioblastoma Multiforme", "Glioma", "GBM", "Glioma, Malignant", "Glioblastoma Multiforme of Brain"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04163289",
          "briefTitle": "Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04677413",
          "briefTitle": "Ultra-fractionated Radiotherapy for Rectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04234113",
          "briefTitle": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Thyroid Cancer", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Melanoma", "Merkel Cell Carcinoma", "Skin Squamous Cell Carcinoma", "Microsatellite Instability High", "Triple Negative Breast Cancer", "Mesothelioma", "Thymic Cancer", "Cervical Cancer", "Biliary Tract Cancer", "Hepatocellular Carcinoma", "Ovarian Cancer", "Gastric Cancer", "Head and Neck Squamous Cell Carcinoma", "Anal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 115,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03727789",
          "briefTitle": "CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cutaneous Melanoma of the Extremity", "Advanced Sarcoma of the Extremity", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma of the Extremity", "Recurrent Sarcoma of the Extremity", "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02761291",
          "briefTitle": "Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03573960",
          "briefTitle": "A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Thyroid Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01283035",
          "briefTitle": "A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-04"
          },
          "completionDateStruct": {
            "date": "2014-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Sarcoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04729608",
          "briefTitle": "Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Platinum-resistant Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 366,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05720117",
          "briefTitle": "Study of PYX-201 in Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor", "Advanced Solid Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 330,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06041490",
          "briefTitle": "Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Liver Transplant; Complications", "Hepatocarcinoma", "Recurrent Osteosarcoma", "High-Risk Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 88,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01012297",
          "briefTitle": "Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-11"
          },
          "completionDateStruct": {
            "date": "2015-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Uterine Corpus Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Corpus Leiomyosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00096447",
          "briefTitle": "Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-11"
          },
          "completionDateStruct": {
            "date": "2011-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Endometrial Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04486352",
          "briefTitle": "A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06704152",
          "briefTitle": "BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["AML, Adult Recurrent", "ALL, Recurrent, Adult", "MDS"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05455658",
          "briefTitle": "STEMVAC in Patients With Early Stage Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01938833",
          "briefTitle": "Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-12-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["HER2-negative Breast Cancer", "Inflammatory Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06265285",
          "briefTitle": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Esophageal Squamous Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Esophageal Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Carcinoma", "Locally Advanced Urothelial Carcinoma", "Lung Non-Small Cell Carcinoma", "Malignant Solid Neoplasm", "Metastatic Colorectal Carcinoma", "Metastatic Cutaneous Melanoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Unresectable Cutaneous Melanoma", "Unresectable Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "Unresectable Urothelial Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02773849",
          "briefTitle": "ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-09-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Superficial Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 157,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05996185",
          "briefTitle": "Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["T Cell Lymphoma", "T-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.2": [
      {
        "identificationModule": {
          "nctId": "NCT00729053",
          "briefTitle": "Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-06"
          },
          "completionDateStruct": {
            "date": "2008-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 92,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07067437",
          "briefTitle": "Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01476839",
          "briefTitle": "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-11-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Adult Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03556384",
          "briefTitle": "Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastrointestinal Stromal Tumors", "Sdh", "GIST", "Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04046133",
          "briefTitle": "Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anal Cancer Stage III A", "Anal Cancer Stage III B"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02780648",
          "briefTitle": "Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-05-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04821778",
          "briefTitle": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Esophagus Cancer", "Esophagogastric Junction Cancer", "Chemoradiation", "Targeted Therapy", "Immunotherapy", "Chemotherapy Effect"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07183878",
          "briefTitle": "Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "High-Risk Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "High-Risk Myelodysplastic Syndromes"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 138,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00393094",
          "briefTitle": "Bevacizumab and Irinotecan to Treat Brain Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-09"
          },
          "completionDateStruct": {
            "date": "2010-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "High-Grade Gliomas"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03476239",
          "briefTitle": "Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-04-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Lymphoblastic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 121,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02880371",
          "briefTitle": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-10-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05622071",
          "briefTitle": "Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma by BCLC Stage"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03104699",
          "briefTitle": "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cancer", "Cervical Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 211,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06328036",
          "briefTitle": "Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Glioblastoma, IDH-Wildtype"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00695409",
          "briefTitle": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-03-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 122,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02910063",
          "briefTitle": "Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "B-Cell Non Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01772004",
          "briefTitle": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-12-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1756,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02625610",
          "briefTitle": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 499,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05669846",
          "briefTitle": "Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04435691",
          "briefTitle": "Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 110,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00602797",
          "briefTitle": "Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-12-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-08-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01926197",
          "briefTitle": "Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-08-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-09-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06871410",
          "briefTitle": "Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01408160",
          "briefTitle": "Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-06-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult B Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03237780",
          "briefTitle": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma", "Unresectable Urethral Urothelial Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06770582",
          "briefTitle": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-02-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Muscle Invasive Bladder Urothelial Carcinoma", "Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma", "Stage I Bladder Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00070525",
          "briefTitle": "Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2003-11"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Childhood High-grade Cerebral Astrocytoma", "Childhood Oligodendroglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04807140",
          "briefTitle": "Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06340568",
          "briefTitle": "A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 504,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03528408",
          "briefTitle": "Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Ocular Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04616040",
          "briefTitle": "A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1030,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04137640",
          "briefTitle": "Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-19",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04577950",
          "briefTitle": "A Prospective Study Comparing Three Injection Sites to Detect Sentinel Lymph Nodes in Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06637423",
          "briefTitle": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Muscle Invasive Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02652715",
          "briefTitle": "Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-11-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Nasal Type Extranodal NK/T-Cell Lymphoma", "Adult T-Cell Leukemia/Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "B Lymphoblastic Leukemia/Lymphoma", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Burkitt Leukemia", "Central Nervous System Lymphoma", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Diffuse Large B-Cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3 Follicular Lymphoma", "Hepatosplenic T-Cell Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle Cell Lymphoma", "Mediastinal (Thymic) Large B-Cell Lymphoma", "Mycosis Fungoides", "Nasal Type Extranodal NK/T-Cell Lymphoma", "Nodal Marginal Zone Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Post-Transplant Lymphoproliferative Disorder", "Primary Cutaneous Anaplastic Large Cell Lymphoma", "Primary Effusion Lymphoma", "Sezary Syndrome", "Splenic Marginal Zone Lymphoma", "Subcutaneous Panniculitis-Like T-Cell Lymphoma", "Systemic Anaplastic Large Cell Lymphoma", "T Lymphoblastic Leukemia/Lymphoma", "Transformed Recurrent Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00131989",
          "briefTitle": "Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-06"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07198074",
          "briefTitle": "Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-03-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Endometrial Carcinoma", "Recurrent Endometrial Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 255,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05617040",
          "briefTitle": "Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00659568",
          "briefTitle": "Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-03"
          },
          "completionDateStruct": {
            "date": "2010-08"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Endometrial Cancer", "Kidney Cancer", "Lung Cancer", "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01642082",
          "briefTitle": "Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-09"
          },
          "completionDateStruct": {
            "date": "2016-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mixed Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06734702",
          "briefTitle": "Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11-29",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Neoadjuvant Therapy", "Concurrent Chemoradiotherapy", "Immunotherapy", "Locally Advanced Non-Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 497,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06498622",
          "briefTitle": "Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-05-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01193842",
          "briefTitle": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-10-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["AIDS-Related Plasmablastic Lymphoma", "AIDS-Related Primary Effusion Lymphoma", "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage I Grade 3 Follicular Lymphoma", "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "HIV Infection", "Plasmablastic Lymphoma", "Primary Effusion Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03425773",
          "briefTitle": "Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-05-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Stomach Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02437370",
          "briefTitle": "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter", "Recurrent Bladder Carcinoma", "Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter", "Regional Urothelial Carcinoma of the Renal Pelvis and Ureter", "Stage III Bladder Urothelial Carcinoma", "Stage III Urethral Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Urethral Cancer", "Urethral Urothelial Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01925131",
          "briefTitle": "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-01-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Leukemias of Ambiguous Lineage", "B-cell Adult Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00138177",
          "briefTitle": "Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer", "Unspecified Adult Solid Tumor, Protocol Specific"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01432886",
          "briefTitle": "A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-10"
          },
          "completionDateStruct": {
            "date": "2013-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "20 Years",
          "maximumAge": "74 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05430373",
          "briefTitle": "GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumors, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06636175",
          "briefTitle": "64Cu-LLP2A for Imaging Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Low-Grade Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Lymphoplasmacytic Lymphoma", "Small Lymphocytic Lymphoma", "Chronic Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00751101",
          "briefTitle": "Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-08-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-03-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Chemotherapeutic Agent Toxicity", "Palmar-plantar Erythrodysesthesia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03162627",
          "briefTitle": "Selumetinib and Olaparib in Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-08-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Malignant Neoplasm of Breast", "Malignant Neoplasms of Digestive Organs", "Malignant Neoplasms of Female Genital Organs", "Malignant Neoplasms of Male Genital Organs", "Malignant Neoplasms of Thyroid and Other Endocrine Glands"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06161272",
          "briefTitle": "Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-01-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "High Grade Serous Adenocarcinoma of Ovary", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01064622",
          "briefTitle": "Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-01-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 118,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03070431",
          "briefTitle": "High-precision Radiotherapy of Motor Deficits Due to Metastatic Spinal Cord Compression"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-02-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Spinal Cord Compression Due to Metastasis to Spine"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 44,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07198945",
          "briefTitle": "Six Versus Twelve Month Index Follow-up After Large Colon Polyp Resection"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Cancer", "Colon Polyp", "Adenoma", "Serrated Polyp", "Recurrence, Local Neoplasm", "Endoscopic Resection"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 546,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03686345",
          "briefTitle": "Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Core Binding Factor Acute Myeloid Leukemia (CBF-AML)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02978404",
          "briefTitle": "Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-06-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Clear-Cell Metastatic Renal Cell Carcinoma", "Non Small Cell Lung Cancer Metastatic", "Brain Metastases, Adult", "Small Cell Lung Cancer", "Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02315326",
          "briefTitle": "Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)", "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 109,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03551626",
          "briefTitle": "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-09-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Malignant Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 552,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04197076",
          "briefTitle": "Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-02-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02005289",
          "briefTitle": "Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-01-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Contiguous Stage II Small Lymphocytic Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Prolymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage I Chronic Lymphocytic Leukemia", "Stage I Small Lymphocytic Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage III Small Lymphocytic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00280150",
          "briefTitle": "Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-01"
          },
          "completionDateStruct": {
            "date": "2013-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05123950",
          "briefTitle": "A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Squamous Cell Carcinoma of the Head and Neck"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 304,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02163317",
          "briefTitle": "Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-02-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02440568",
          "briefTitle": "AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00195260",
          "briefTitle": "Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-10"
          },
          "completionDateStruct": {
            "date": "2007-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 151,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00265785",
          "briefTitle": "S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-07"
          },
          "completionDateStruct": {
            "date": "2011-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04296578",
          "briefTitle": "Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancer", "Castrate Resistant Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03383575",
          "briefTitle": "Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Blasts 20-30 Percent of Bone Marrow Nucleated Cells", "Chronic Myelomonocytic Leukemia", "IDH2 Gene Mutation", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory High Risk Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05945875",
          "briefTitle": "Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05169957",
          "briefTitle": "Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma, Ocular", "Melanoma, Cutaneous", "Metastatic Melanoma", "Melanoma, Mucosal", "Liver Metastases"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04367090",
          "briefTitle": "Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 97,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02170389",
          "briefTitle": "Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-10-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Renal Cell Carcinoma", "Stage I Renal Cell Cancer", "Stage II Renal Cell Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02666950",
          "briefTitle": "WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02332850",
          "briefTitle": "Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-01-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 83,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02337491",
          "briefTitle": "Pembrolizumab +/- Bevacizumab for Recurrent GBM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-09-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04979078",
          "briefTitle": "Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hand-foot Syndrome", "Hand-foot Skin Reaction"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01324635",
          "briefTitle": "Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-05"
          },
          "completionDateStruct": {
            "date": "2016-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Glioma", "High-grade Meningioma", "Brain Metastasis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01208974",
          "briefTitle": "Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-03-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Ductal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03275558",
          "briefTitle": "Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-07-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Glioblastoma", "Gliosarcoma", "Anaplastic Gliomas"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02523313",
          "briefTitle": "Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Malignant Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 167,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01468909",
          "briefTitle": "Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-01-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 106,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04983121",
          "briefTitle": "Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-08-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06856213",
          "briefTitle": "Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01380782",
          "briefTitle": "BIBF 1120 for Recurrent High-Grade Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-05"
          },
          "completionDateStruct": {
            "date": "2014-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04458922",
          "briefTitle": "Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-13",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Central Chondrosarcoma, Grade 2", "Central Chondrosarcoma, Grade 3", "Dedifferentiated Chondrosarcoma", "Metastatic Clear Cell Sarcoma of Soft Tissue", "Metastatic Primary Central Chondrosarcoma", "Unresectable Primary Central Chondrosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00891137",
          "briefTitle": "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-04"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia", "Lymphoma", "Multiple Myeloma", "Plasma Cell Neoplasm", "Myelodysplastic Syndromes"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00052442",
          "briefTitle": "10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-08"
          },
          "completionDateStruct": {
            "date": "2009-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06042569",
          "briefTitle": "Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-09-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-03-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 174,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06524583",
          "briefTitle": "Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Leiomyosarcoma Uterus"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 198,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00980343",
          "briefTitle": "GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-02"
          },
          "completionDateStruct": {
            "date": "2012-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 44,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06762080",
          "briefTitle": "Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Leptomeningeal Metastasis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04943627",
          "briefTitle": "Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-10-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cancer", "Metastatic Cervical Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06534983",
          "briefTitle": "A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2034-01-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Muscle-invasive Urothelial Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 362,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03505554",
          "briefTitle": "A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Anaplastic Large Cell Lymphoma, ALK-Positive"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03324802",
          "briefTitle": "Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage I Breast Cancer AJCC v7", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04313868",
          "briefTitle": "GEN2 Directed Cancer Immunotherapy Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Carcinoma", "Metastatic Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03161353",
          "briefTitle": "Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-06-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 377,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01011439",
          "briefTitle": "Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-12-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Thymic Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ]
  }
}
